Evercore ISI analyst Vijay Kumar raised the firm’s price target on Boston Scientific (BSX) to $100 from $95 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $101 from $97 at BTIG
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific price target raised to $110 from $100 at Truist
- FDA says Boston Scientific Accolade pacemakers may need early replacement
- Boston Scientific price target raised to $110 from $100 at TD Cowen